WO2023101993 - SEGMENTED NUCLEIC ACIDS
National phase entry:
Publication Number
WO/2023/101993
Publication Date
08.06.2023
International Application No.
PCT/US2022/051309
International Filing Date
30.11.2022
Title **
[English]
SEGMENTED NUCLEIC ACIDS
[French]
ACIDES NUCLÉIQUES SEGMENTÉS
Applicants **
ZHONG, Minghong
Inventors
ZHONG, Minghong
Priority Data
17/839,539
14.06.2022
US
63/284,025
30.11.2021
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
USPTO
* |
| * | |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Natural Person
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2735 | |
| EPO | Filing, Examination, Granting | 13390 | |
| Japan | Filing, Examination, Granting | 2546 | |
| South Korea | Filing, Examination, Granting | 2789 | |
| USA | Filing, Examination, Granting | 7310 |
Total:
28,770
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
Provided herein are processes and methods for preparation of segmented nucleic acids and segmented nucleic acid conjugates comprising at least two non-nucleotide linkers, and their RNP complexes with RNA guided gene editing proteins including CRISPR Cas proteins and ADAR enzymes. Also disclosed are the uses of the compositions comprising segmented nucleic acids or segmented nucleic acid conjugates as medicinal agents for treatment of diseases.[French]
La présente divulgation concerne des processus et des procédés de préparation d'acides nucléiques segmentés et de conjugués d'acides nucléiques segmentés comprenant au moins deux lieurs non nucléotidiques, et leurs complexes RNP avec des protéines d'édition génique guidée par ARN comprenant des protéines CRISPR-Cas et des enzymes ADAR. La divulgation concerne également les utilisations des compositions comprenant des acides nucléiques segmentés ou des conjugués d'acides nucléiques segmentés en tant qu'agents médicamenteux pour le traitement de maladies.